HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP
Recruiting
N/A
Interventional Study
Endoscopic Retrograde Cholangiopancreatography
Hypoxemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 84
- Sex
- Any
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 74 (estimated)
- Sponsor
- Kocaeli University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal ox…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 18 to 84 years
* ASA physical status I-III
* Patients scheduled to undergo ERCP
* Patients who provide written informed consent
Exclusion Criteria:
* Recent history of upper respiratory tract infection
* History of lung cancer
* Chronic obstructive pulmonary di…
Contacts